Therapeutic treatment of breast cancer based on c-MAF status
US11596642B2 · kind B2 · utility
5Cited by
19References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 25, 2017 |
| Grant date | Mar 7, 2023 |
| Priority date | — |
| Expiry date | Aug 30, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/158
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding or preventing bone degradation. In some embodiments, the agent for avoiding or preventing bone degradation is zoledronic acid.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.